A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.
This study has been terminated.
(Low recruitment rate due to treatment regimen change)
Information provided by:
First received: April 16, 2007
Last updated: June 27, 2008
Last verified: June 2008
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been terminated.|
|Study Completion Date:||June 2008|
|Estimated Primary Completion Date:||No date given|